当前位置： SCI文献检索 > BONE MARROW TRANSPLANTATION期刊下所有文献 > Rescuing the neonatal brain from hypoxic injury with autologous cord blood.

Rescuing the neonatal brain from hypoxic injury with autologous cord blood.

Abstract：

:Brain injury resulting from perinatal hypoxic-ischemic encephalopathy (HIE) is a major cause of acute mortality in infants and chronic neurologic disability in surviving children. Recent multicenter clinical trials demonstrated the effectiveness of hypothermia initiated within the first 6 postnatal hours to reduce the risk of death or major neurological disabilities among neonates with HIE. However, in these trials, approximately 40% of cooled infants died or survived with significant impairments. Therefore, adjunct therapies are required to improve the outcome in neonates with HIE. Cord blood (CB) is a rich source of stem cells. Administration of human CB cells in animal models of HIE has generally resulted in improved outcomes and multiple mechanisms have been suggested including anti-inflammation, release of neurotrophic factors and stimulation of endogenous neurogenesis. Investigators at Duke are conducting studies of autologous CB infusion in neonates with HIE and in children with cerebral palsy. These pilot studies indicate no added risk from the regimens used, but results of ongoing placebo-controlled trials are needed to assess efficacy. Meanwhile, further investigations are warranted to determine the best strategies, that is, timing, dosing, route of delivery, choice of stem cells and ex vivo modulations, to attain long-term benefits of CB stem cell therapy.

journal_name

Bone Marrow Transplant

journal_title

Bone marrow transplantation

authors

Liao Y,Cotten M,Tan S,Kurtzberg J,Cairo MS

doi

10.1038/bmt.2012.169

subject

Has Abstract

pub_date

2013-07-01 00:00:00

pages

890-900

issue

7

eissn

0268-3369

issn

1476-5365

pii

bmt2012169

journal_volume

48

pub_type

杂志文章,评审

相关文献

BONE MARROW TRANSPLANTATION文献大全
  • Graft failure in children receiving HLA-mismatched marrow transplants with busulfan-containing regimens.

    abstract：:Identifying risk factors that lead to graft failure may reduce morbidity and mortality after bone marrow transplantation (BMT) for hematologic malignancies. We evaluated engraftment of all patients with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and myelodysplastic syndrome (MDS) receiving an...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Schultz KR,Ratanatharathorn V,Abella E,Eisenbrey AB,Karanes C,Lum LG,de Planque MM,Uberti JP,Ravindranath Y,Sensenbrenner LL

    更新日期：1994-06-01 00:00:00

  • Bone marrow graft as a source of allogeneic hematopoietic stem cells in patients undergoing a reduced intensity conditioning regimen.

    abstract：:In an attempt to reduce the incidence of chronic GVHD (cGVHD) after reduced-intensity conditioning (RIC), we used BM instead of PBSC and added melphalan 100 mg/m(2) to the classical association of fludarabine, 30 mg/m(2)/day for 3 days and TBI, 200 cGy (FLUIM regimen). Between 2000 and 2012, 51 patients received BM wi...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2014.193

    authors： Gomez E,Duléry R,Langlois C,Coiteux V,Terriou L,Magro L,Gauthier J,de Berranger E,Duhamel A,Yakoub-Agha I

    更新日期：2014-12-01 00:00:00

  • Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT.

    abstract：:This retrospective analysis compared two regimens of fludarabine combined with i.v. BU 6.4 mg/kg (FB2) or BU 12.8 mg/kg (FB4) for allografting of AML in first CR. A total of 437 patients (median age: 50 years) were administered FB2 (n = 225, 51%) or FB4 (n = 212, 49%). Median follow-up time was 28 months. Use of FB2 r...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/bmt.2014.133

    authors： Kharfan-Dabaja MA,Labopin M,Bazarbachi A,Hamladji RM,Blaise D,Socié G,Lioure B,Bermudez A,Lopez-Corral L,Or R,Arcese W,Fegueux N,Nagler A,Mohty M

    更新日期：2014-09-01 00:00:00

  • Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and ce

    abstract：:We evaluated the 100-day mortality rates associated with busulfan-based myeloablative conditioning regimens based on data from 1812 chronic myelogenous leukemia patients who underwent allogeneic blood or marrow transplantation (allotx). In all, 47 patients received intravenous (i.v.) busulfan and cyclophosphamide (i.v...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/sj.bmt.1704461

    authors： Thall PF,Champlin RE,Andersson BS

    更新日期：2004-06-01 00:00:00

  • Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers.

    abstract：:Adoptive immunotherapy with allogeneic purified natural killer (NK) cell products might exert graft-versus-tumor alloreactivity with little risk of GVHD. In a prospective phase II study in two centers, we administered purified NK cell products to high-risk patients treated with haploidentical T-cell-depleted SCT. Sixt...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/bmt.2012.162

    authors： Stern M,Passweg JR,Meyer-Monard S,Esser R,Tonn T,Soerensen J,Paulussen M,Gratwohl A,Klingebiel T,Bader P,Tichelli A,Schwabe D,Koehl U

    更新日期：2013-03-01 00:00:00

  • Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia.

    abstract：:Allogeneic BMT is potentially curative for patients with acute myelogenous leukemia (AML) in first remission. However, many patients relapse after transplantation. Various immunotherapeutic options have been attempted with variable success in preventing relapse. Early identification of patients at high risk for relaps...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1703262

    authors： Kumar S,Chen MG,Gastineau DA,Gertz MA,Inwards DJ,Lacy MQ,Tefferi A,Litzow MR

    更新日期：2001-11-01 00:00:00

  • Amiodarone and cyclophosphamide: potential for enhanced lung toxicity.

    abstract：:Antineoplastic therapy can be associated with drug-induced lung toxicity. With the increasing use of amiodarone for cardiac dysrhythmias there is an increasing possibility of its combined use with chemotherapies for various malignancies. We report a patient on long-term amiodarone who developed biopsy-proven drug-indu...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1703039

    authors： Bhagat R,Sporn TA,Long GD,Folz RJ

    更新日期：2001-05-01 00:00:00

  • Unrelated donor marrow transplantation in children: transplant policy and outcome in Leiden Paediatrics SCT-Centre.

    abstract：:The transplant policy for unrelated donor (UD) BMT at Leiden Paediatrics' SCT-Centre consisted of the use of (1) fully HLA-matched donors or, if not available, HLA-class I matched and/or cytotoxic T-lymphocyte precursor (CTLp)-negative donors and (2) protective isolation of the recipient and antimicrobial suppression ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2009.104

    authors： Vossen JM,Donker AE,Heemskerk MB,Lie JL,van Weel-Sipman MH,Bredius RG,Bakker JD,Egeler RM,Oudshoorn M

    更新日期：2010-01-01 00:00:00

  • Allogeneic transplantation of purified CD34+ cells from peripheral blood: Spanish experience of 62 cases. Spanish Group of allo-PBT.

    abstract：:This report summarizes the Spanish experience of 62 cases of allogeneic transplantation of purified CD34+ cells from peripheral blood. HLA-identical sibling donors received G-CSF. After leukapheresis, peripheral blood progenitor cells were purified using one of two methods: Ceprate (n = 38), or Isolex 300 (n = 24). Si...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Urbano-Ispizua A,Solano C,Brunet S,de la Rubia J,Odriozola J,Zuazu J,Figuera A,Caballero D,Martínez C,García J,Sanz G,Torrabadella M,Alegre A,Pérez-Oteiza J,Jurado M,Oyonarte S,Sierra J,García-Conde J,Rozman C

    更新日期：1998-06-01 00:00:00

  • Phase IIa cross-over study of propylene glycol-free melphalan (LGD-353) and alkeran in multiple myeloma autologous transplantation.

    abstract：:Propylene Glycol-Free melphalan HCL for Injection (PGF-Mel) is a new formulation that incorporates Captisol, a specially modified cyclodextrin, to improve melphalan stability. In this phase IIa, open-label, randomized, cross-over design bioequivalence study, the pharmacokinetics of PGF-Mel were compared with the marke...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1038/bmt.2014.120

    authors： Aljitawi OS,Ganguly S,Abhyankar SH,Ferree M,Marks R,Pipkin JD,McGuirk JP

    更新日期：2014-08-01 00:00:00

  • Effect of pentoxifylline on regimen related toxicity in patients undergoing allogeneic or autologous bone marrow transplantation.

    abstract：:An unblinded, historical controlled study of 49 bone marrow transplant (BMT) patients was carried out in our institution to assess the effect of oral pentoxifylline (PTX) on BMT regimen related toxicity (RRT). Twenty-eight consecutively treated BMT patients (17 allogeneic, 11 autologous) were entered into the PTX trea...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：

    authors： van der Jagt RH,Pari G,McDiarmid SA,Boisvert DM,Huebsch LB

    更新日期：1994-02-01 00:00:00

  • Combination of a haploidentical SCT with an unrelated cord blood unit: a single-arm prospective study.

    abstract：:We conducted a single-arm prospective study in 50 patients who received the combination of an haploidentical stem cell graft and an unrelated umbilical cord blood unit for the treatment of hematological malignancies. The median time for neutrophil engraftment was 13 days (11-20 days), and for platelets was 15 days (11...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2013.154

    authors： Chen J,Wang RX,Chen F,Sun AN,Qiu HY,Jin ZM,Tang XW,Han Y,Fu ZZ,He GS,Miao M,Ma X,Wu DP

    更新日期：2014-02-01 00:00:00

  • Optimal timing of G-CSF administration after CD34+ immunoselected peripheral blood progenitor cell transplantation.

    abstract：:G-CSF accelerates neutrophil recovery after autologous peripheral blood progenitor cell transplantation (aPBPCT), although the optimal timing for its administration is currently unknown. In order to establish the role and the optimal timing of administration of G-CSF after immunoselected CD34+ aPBPCT, we analyzed the ...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1038/sj.bmt.1701795

    authors： Piccirillo N,Sica S,Laurenti L,Chiusolo P,La Barbera EO,Sorà F,Leone G

    更新日期：1999-06-01 00:00:00

  • Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.

    abstract：:The CXCR4-inhibitor plerixafor mobilizes hematopoietic stem cells amplifying the effects of granulocyte-CSF (G-CSF). Before approval plerixafor was used in a compassionate use program (CUP) for patients who failed a previous mobilization. In the German CUP 60 patients from 23 centers (median age 56.5 years (2-75)) wer...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1038/bmt.2010.249

    authors： Hübel K,Fresen MM,Salwender H,Basara N,Beier R,Theurich S,Christopeit M,Bogner C,Galm O,Hartwig R,Heits F,Lordick F,Rösler W,Wehler D,Zander AR,Albert MH,Dressler S,Ebinger M,Frickhofen N,Hertenstein B,Kiehl M,L

    更新日期：2011-08-01 00:00:00

  • Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens.

    abstract：:We investigated the impact of the most commonly used preparative regimens on the outcome of 395 patients with diffuse large cell lymphoma (DLCL), consecutively reported to the registry of the Spanish GEL/TAMO. Among them, 139 (35%) were autografted in 1st CR, 86 (22%) in 2nd/3rd CR, 124 (31%) had chemosensitive diseas...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/sj.bmt.1702795

    authors： Salar A,Sierra J,Gandarillas M,Caballero MD,Marín J,Lahuerta JJ,García-Conde J,Arranz R,León A,Zuazu J,García-Laraña J,López-Guillermo A,Sanz MA,Grañena A,García JC,Conde E,GEL\/TAMO Spanish Cooperative Group.

    更新日期：2001-02-01 00:00:00

  • Non-radiotherapy conditioning with stem cell transplantation from alternative donors in children with refractory severe aplastic anemia.

    abstract：:Conditioning including total body/lymphoid irradiation is widely used to prevent graft rejection in patients with refractory severe aplastic anemia (SAA) undergoing hemopoietic cell transplantation (HCT) from alternative donors and or after graft manipulation. To reduce regimen-related toxicity we transplanted three c...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1704792

    authors： Urban C,Benesch M,Sykora KW,Schwinger W,Lackner H

    更新日期：2005-03-01 00:00:00

  • Value and affordability of CAR T-cell therapy in the United States.

    abstract：:In the United States the increasing number of Food and Drug Administration (FDA)-approved, innovative, and potentially effective commercial cancer therapies pose a significant financial burden on public and private payers. Chimeric antigen receptor (CAR) T cells are prototypical of this challenge. In 2017 and 2018, ti...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/s41409-020-0956-8

    authors： Fiorenza S,Ritchie DS,Ramsey SD,Turtle CJ,Roth JA

    更新日期：2020-09-01 00:00:00

  • Valacyclovir prophylaxis for the prevention of Herpes simplex virus reactivation in recipients of progenitor cells transplantation.

    abstract：:HSV can cause oral lesions that exacerbate chemotherapy-related mucositis. Intravenous acyclovir is effective in preventing HSV reactivations, but expensive. Valacyclovir has good bioavailability and has not been studied for prophylaxis of HSV among PCT patients. We compared the efficacy and costs of valacyclovir in p...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.bmt.1703354

    authors： Dignani MC,Mykietiuk A,Michelet M,Intile D,Mammana L,Desmery P,Milone G,Pavlovsky S

    更新日期：2002-02-01 00:00:00

  • Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy.

    abstract：:Bone marrow (BM) angiogenesis is increased in multiple myeloma and is an important prognostic factor. However, prior studies were mainly done on patients receiving conventional chemotherapy and there is limited data on its prognostic value in patients undergoing high-dose therapy (HDT) as initial therapy. We studied B...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1704555

    authors： Kumar S,Gertz MA,Dispenzieri A,Lacy MQ,Wellik LA,Fonseca R,Lust JA,Witzig TE,Kyle RA,Greipp PR,Rajkumar SV

    更新日期：2004-08-01 00:00:00

  • Severe migratory polyarthritis following in vivo CAMPATH-1G.

    abstract：:CAMPATH-1G is an IgG2b rat antihuman (CDw52) monoclonal antibody (MoAb) which is currently being used for T cell depletion in the setting of allogeneic bone marrow transplantation (BMT). In addition it elicits substantial lymphoid depletion, an effect which is being explored for remission induction in patients with ly...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Varadi G,Or R,Rund D,Orbach H,Slavin S,Nagler A

    更新日期：1995-12-01 00:00:00

  • Transplantation with peripheral blood stem cells, manipulated or unmanipulated, for the treatment of high-risk childhood leukemia.

    abstract：:Collection of peripheral blood stem cells (PBSC) does not require anesthesia or multiple marrow aspirations, and hence, is far less invasive than bone marrow collection. Most importantly, PBSC can be collected from the body's entire pool of HSC to provide more stem cells than marrow aspiration performed at localized i...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：

    authors： Takaue Y,Kawano Y,Watanabe T,Watanabe A

    更新日期：1998-12-01 00:00:00

  • Growth hormone treatment impact on growth rate and final height of patients who received HSCT with TBI or/and cranial irradiation in childhood: a report from the French Leukaemia Long-Term Follow-Up Study (LEA).

    abstract：:The literature contains a substantial amount of information about factors that adversely influence the linear growth in up to 85% of patients undergoing haematopoietic SCT (HSCT) with TBI and/or cranial irradiation (CI) for acute leukaemia (AL). By contrast, only a few studies have evaluated the impact of growth hormo...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2011.139

    authors： Isfan F,Kanold J,Merlin E,Contet A,Sirvent N,Rochette E,Poiree M,Terral D,Carla-Malpuech H,Reynaud R,Pereira B,Chastagner P,Simeoni MC,Auquier P,Michel G,Deméocq F

    更新日期：2012-05-01 00:00:00

  • Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin.

    abstract：:Between February 1998 and October 1999, 24 patients with advanced leukemia, lymphoma or solid tumors received G-CSF mobilized peripheral blood stem cells (PBSC) from HLA-matched sibling donors after dose-reduced conditioning therapy. Only patients with reduced performance status or major infectious complications, not ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702500

    authors： Bornhäuser M,Thiede C,Schuler U,Platzbecker U,Freiberg-Richter J,Helwig A,Plettig R,Röllig C,Naumann R,Kroschinsky F,Neubauer A,Ehninger G

    更新日期：2000-07-01 00:00:00

  • Allogeneic SCT in refractory or relapsed adult ALL is effective without prior reinduction chemotherapy.

    abstract：:We present 60 patients with refractory (n=8) or relapsed (n=52) adult ALL who received allogeneic hematopoietic SCT (HSCT) with (n=41) or without (n=19) prior reinduction chemotherapy. In our center, omission of reinduction is recommended if a suitable donor is promptly available, tumor burden is moderate and disease ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2008.258

    authors： Terwey TH,Massenkeil G,Tamm I,Hemmati PG,Neuburger S,Martus P,Dörken B,Hoelzer D,Arnold R

    更新日期：2008-12-01 00:00:00

  • Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: a randomized evaluation of early vs late administration of recombinant human G-CSF.

    abstract：:The optimal timing for recombinant human (rh)G-CSF administration after chemotherapy for PBSC mobilization has not yet been determined. In this study, we compared two different time schedules of rhG-CSF; 4th (early) vs 7th day (late), in 48 consecutive patients with multiple myeloma and lymphoma undergoing PBSC mobili...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1038/bmt.2009.161

    authors： Ozcelik T,Topcuoglu P,Beksac M,Ozcan M,Arat M,Biyikli Z,Bakanay SM,Ilhan O,Gurman G,Arslan O,Demirer T

    更新日期：2009-12-01 00:00:00

  • Intermediate-dose busulfan and cyclophosphamide as a conditioning regimen for bone marrow transplantation in a case of Fanconi anemia in myelodysplastic transformation.

    abstract：:We report an 11-year old female with myelodysplastic (refractory anemia with excess of blasts) presentation of Fanconi anemia. After failure of initial chemotherapy with low doses of 6-mercaptopurine and prednisolone she underwent allogeneic bone marrow transplantation (BMT) from her HLA-matched sibling. Busulfan 8 mg...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1700662

    authors： Maschan AA,Kryzanovskii OI,Yourlova MI,Skorobogatova EV,Pashanov ED,Potapova YE,Timonova LA,Bogatcheva NY,Samochatova EV,Roumjantzev AG

    更新日期：1997-02-01 00:00:00

  • Low T-cell chimerism is not followed by graft rejection after nonmyeloablative stem cell transplantation (NMSCT) with CD34-selected PBSC.

    abstract：:We investigate the feasibility of CD34-selected peripheral blood stem cell (PBSC) transplantation followed by pre-emptive CD8-depleted donor lymphocyte infusions (DLI) after a minimal conditioning regimen. Six patients with advanced hematological malignancies ineligible for a conventional myeloablative transplant (n=5...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.bmt.1704220

    authors： Baron F,Baudoux E,Frère P,Tourqui S,Schaaf-Lafontaine N,Herens C,DePrijck B,Fillet G,Beguin Y

    更新日期：2003-10-01 00:00:00

  • Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results.

    abstract：SUMMARY:High-dose busulfan is an important component of myeloablative regimens. Variable drug exposure may occur following oral administration. Therefore, the use of intravenous busulfan has been advocated. Previous work has suggested a cumulative dosage of 16 mg/kg for haematopoietic transplantation in children less t...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1704209

    authors： Dalle JH,Wall D,Theoret Y,Duval M,Shaw L,Larocque D,Taylor C,Gardiner J,Vachon MF,Champagne MA

    更新日期：2003-10-01 00:00:00

  • Introduction: current issues in high-dose chemotherapy and stem cell support.

    abstract：:In the 1980s it became clear that low numbers of primitive hematopoietic cells were present in the peripheral bloodstream. Early clinical trials by investigators in the USA, Australia, and Germany demonstrated that these cells could be collected and reinfused to support high-dose chemotherapy procedures in patients ot...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/sj.bmt.1701667

    authors： Shea TC

    更新日期：1999-05-01 00:00:00

  • Hexaminolevulinate-mediated photodynamic purging of marrow grafts with murine breast carcinoma.

    abstract：:Photodynamic therapy (PDT) with porphyrin precursors is an established therapy for certain tumors. This study aimed to explore the use of hexaminolevulinate (HAL), a porphyrin precursor, for photodynamic purging of BM grafts contaminated with cells of the 4T1 breast carcinoma cell line. The optimal PDT dose was not ef...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2010.277

    authors： Čunderlíková B,Vasovič V,Sieber F,Furre T,Borgen E,Nesland JM,Peng Q

    更新日期：2011-08-01 00:00:00